Safety and Immunogenicity of a Protein Particle Malaria Vaccine Candidate, R21, Administered With and Without Matrix-M1 in Healthy UK Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs R 21 (Primary) ; Matrix M
- Indications Malaria
- Focus Adverse reactions
- 08 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.
- 08 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017.
- 06 Jul 2017 Status changed from recruiting to active, no longer recruiting.